Filing Flows › Comparisons › OSCR vs TRUP
Oscar Health vs Trupanion: OSCR and TRUP compared
Oscar Health is the larger company: $5.1B of revenue in its latest quarter (Q3 2026) against $406M for Trupanion (Q3 2026). Oscar Health is growing faster (+72% against +10% a year earlier). Oscar Health is more profitable, with an operating margin of 3.5% against 2.4%.
Where the money goes: OSCR and TRUP
Oscar Health (OSCR) · Q3 2026
Oscar Health, Q3 2026: revenue $5.1B (+72% year over year), operating margin 3.5%, net earnings $167M, operating cash flow −$1.2B. The chart follows the revenue to costs, profit and cash.
Trupanion (TRUP) · Q3 2026
Trupanion, Q3 2026: revenue $406M (+10% year over year), operating margin 2.4%, net earnings $9.3M, operating cash flow $30.7M. The chart follows the revenue to costs, profit and cash.
| Oscar Health (OSCR) | Trupanion (TRUP) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $5.1B | $406M |
| Revenue growth, Y/Y | +72% | +10% |
| Operating margin | 3.5% | 2.4% |
| Net earnings | $167M | $9.3M |
| Net margin | 3.3% | 2.3% |
| Operating cash flow | −$1.2B | $30.7M |
| Free cash flow | — | $28.5M |
| Market value | $11.5B | $1.6B |
| P/E | 13.4× | 60.4× |
| Analysts’ mean target | $36.40 | $35.50 |
Where the revenue comes from
Trupanion
- Subscription business: $288M (71%)
- Other Segments: $118M (29%)
Questions
Which is bigger, Oscar Health or Trupanion?
Oscar Health is the larger company: $5.1B of revenue in its latest quarter (Q3 2026) against $406M for Trupanion (Q3 2026).
Is Oscar Health or Trupanion growing faster?
Oscar Health is growing faster (+72% against +10% a year earlier).
Which is more profitable, Oscar Health or Trupanion?
Oscar Health is more profitable, with an operating margin of 3.5% against 2.4%.
More: Oscar Health earnings · how Oscar Health makes money · Trupanion earnings · how Trupanion makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.